The Nerve Growth Factor (NGF) is a well-studied and the first-neurotrophic factor discovered. A trophic factor either in vivo and in vitro, it plays an essential role in the development and survival of certain sympathetic and sensory neurons in both the central and peripheral nervous systems. It can regulate nerve system development, differentiate sympathetic and sensory neurons, promote adult nerve system plasticity and maintenance of structural integrity.NGF elicits a wide variety of responses from its target cells including metabolic changes in gene expression and chemotactic effects. This discovery was defined by the Nobel Foundation as a milestone in developmental neurobiology, and the discoverers, Rita Levi-Montalcini and Stanley Cohen, were awarded the Nobel Prize in Physiology or Medicine in 1986.

NGF exists naturally as a complex referred to as 7S NGF, which contains two molecules of the arginine esteropeptidase γ-subunit, two molecules of the acidic protein α-subunit, one or more zinc ions bound to the γ-subunit and the biologically active 2.5S subunit, also referred to as the β-subunit. The 2.5S subunit is an approximately 26kDa protein composed of two identical 118 amino polypeptide chains held together by noncovalent forces. The 2.5S subunitis entirely responsible for the biological activities of NGF, being the only part of the 7S complex that promotes nerve growth and maintenance of adrenergic neurons in vitro. The additional subunits that comprise 7S NGF appear to protect the 2.5S subunit from proteolytic cleavage.


 Neurotrophic Factor
 Neurotropic Factor
 Enhancing Differentiative Processes

 Role in immune system
 Neuroprotective properties
 Participate in the regulation of apoptosis in neurons
 Inhibit the mitosis of certain type of tumor
 Promote the recovery of injured non-neural tissue
 Delay neuron death induced by the fibers injury
 Promote axon regeneration


NOBEX ®, Mouse Nerve Growth Factor for injection (mNGF),lyophilized powder with the strength of 18ug per vial (>9000AU/vial) launched by Sinobioway Medicine in 2002 is the first therapeutic drug for neural injury in the world commercialized from the outcome of a Nobel prize in Physiology and Medicine.

NOBEX® is a classical drug which can protect the survival of motor neurons, promote axon directional regeneration and myelination. It is the exclusive direct treatment drug for injured neurons. The active ingredient (2.5S NGF) is purified from the submaxillary glands of male mice which has the same biological effect as human endogenous NGF with high purity, high biological activity and high stability, which can efficiently recover exercise and sensory functions in patients, reduce disability rate, and offer high quality life to the patients.

NOBEX® is the first innovator drug launched in Fujian province. Since the product was launched in 2002, Sinobioway Medicine devotes all of its energy to its growth. NOBEX® has a reputation for safety and effectiveness in the area of nerve injury treatment. Not only thousands of academic literatures has been published (NOBEX® was recognized by dozens of medical authorities), but a consensus for NOBEX®’s clinical application has been reached based on millions clinical practices. More encouragingly, NOBEX® has also been incorporated in series books of Interpretation of Clinical Pathway and Therapeutic Drugs by professors from the relative clinical departments. NOBEX®’s treatment effect for injured nerves was further determined in the treatment protocol from clinical department like Neurosurgery, orthopedics, dermatology.